{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:56:08Z","timestamp":1793213768068,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1007\/s40265-019-01073-5","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T14:21:43Z","timestamp":1551190903000},"page":"477-481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Esaxerenone: First Global Approval"],"prefix":"10.1007","volume":"79","author":[{"given":"Sean","family":"Duggan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"issue":"1","key":"1073_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2174\/187152506775268776","volume":"4","author":"P Mulatero","year":"2006","unstructured":"Mulatero P, Milan A, Williams TA, et al. Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovasc Hematol Agents Med Chem. 2006;4(1):75\u201391.","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"8","key":"1073_CR2","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1111\/bcp.13616","volume":"84","author":"M Kato","year":"2018","unstructured":"Kato M, Furuie H, Shimizu T, et al. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects. Br J Clin Pharmacol. 2018;84(8):1821\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1073_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/hr.2016.137","volume":"40","author":"S Shibata","year":"2017","unstructured":"Shibata S, Ishizawa K, Uchida S. Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension. Hypertens Res. 2017;40(3):221\u20135.","journal-title":"Hypertens Res"},{"key":"1073_CR4","unstructured":"Daiichi Sankyo. Esaxerenone (Minnebro): Japanese prescribing information; 2019. \nhttp:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/430574_21490B6F1026_1_02#CONTRAINDICATIONS\n\n. Accessed 15 Jan 2019."},{"key":"1073_CR5","unstructured":"Daiichi Sankyo. Daiichi Sankyo announces approval of MINNEBRO\u2122 tablets for the treatment of hypertension in Japan [media release]. 8 Jan 2019. \nhttps:\/\/www.daiichisankyo.com\n\n."},{"issue":"Suppl 1","key":"1073_CR6","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1097\/01.hjh.0000539672.65099.dd","volume":"36","author":"S Ito","year":"2018","unstructured":"Ito S, Ito H, Rakugi H, et al. A double blind phase III study of esaxerenone (CS-3150) compared to eplerenone in patients with essential hypertension (ESAX-HTN study). J Hypertens. 2018;36(Suppl 1):e239.","journal-title":"J Hypertens"},{"key":"1073_CR7","unstructured":"Daiichi Sankyo. Sankyo and Exelixis sign joint research agreement [media release]. 23 Mar 2016. \nhttps:\/\/www.sec.gov\/Archives\/edgar\/data\/1340156\/000119312506061375\/dex991.htm\n\n."},{"key":"1073_CR8","unstructured":"Exelixis. Exelixis announces first quarter 2006 financial results [media release]. 9 May 2006. \nhttp:\/\/www.exelixis.com\n\n."},{"key":"1073_CR9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","volume":"761","author":"K Arai","year":"2015","unstructured":"Arai K, Homma T, Morikawa Y, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol. 2015;761:226\u201334.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1073_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1124\/jpet.116.234765","volume":"358","author":"K Arai","year":"2016","unstructured":"Arai K, Morikawa Y, Ubukata N, et al. CS-3150, a novel nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate\/salt-induced hypertensive rats. J Pharmacol Exp Ther. 2016;358(3):548\u201357.","journal-title":"J Pharmacol Exp Ther"},{"key":"1073_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","volume":"769","author":"K Arai","year":"2015","unstructured":"Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol. 2015;769:266\u201373.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1073_CR12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1124\/dmd.118.084897","volume":"47","author":"M Yamada","year":"2019","unstructured":"Yamada M, Mendell J, Takakusa H, et al. Pharmacokinetics, metabolism, and excretion of [14C]esaxerenone, a novel mineralocorticoid receptor blocker in humans. Drug Metab Dispos. 2019;47(3):340\u20139.","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 2","key":"1073_CR13","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1097\/01.hjh.0000523471.25362.f5","volume":"35","author":"S Ito","year":"2017","unstructured":"Ito S, Ito H, Rakugi H, et al. Treatment with esaxerenone (CS-3150) is associated with a significant dose dependent antihypertensive effect in essential hypertensive patients [abstract no. BP.02.01]. J Hypertens. 2017;35(Suppl 2):e173.","journal-title":"J Hypertens"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01073-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01073-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01073-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T11:24:20Z","timestamp":1598268260000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01073-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,3,1]]}},"alternative-id":["1073"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01073-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,26]]},"assertion":[{"value":"26 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sean Duggan is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}